Piper Sandler Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price

Halozyme Therapeutics (NASDAQ:HALO) had its price objective lifted by Piper Sandler from $52.00 to $53.00 in a research report report published on Friday morning,Benzinga reports. Piper Sandler currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on HALO. HC Wainwright raised their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday. JMP Securities lifted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Finally, JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.44.

Halozyme Therapeutics Stock Down 1.8 %

Shares of NASDAQ:HALO opened at $52.80 on Friday. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock has a market cap of $6.72 billion, a P/E ratio of 17.48, a P/E/G ratio of 0.44 and a beta of 1.24. The firm has a fifty day moving average price of $50.23 and a 200 day moving average price of $54.00.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently bought and sold shares of HALO. Verdence Capital Advisors LLC raised its stake in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock worth $757,000 after buying an additional 252 shares during the last quarter. GAMMA Investing LLC raised its position in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 412 shares in the last quarter. Juncture Wealth Strategies LLC grew its position in shares of Halozyme Therapeutics by 3.6% in the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock valued at $690,000 after purchasing an additional 415 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its stake in shares of Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 418 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.